/ /

Jennifer A. Webb
Hand-held optical coherence tomography device cleared for marketing
The FDA has cleared for marketing a hand-held spectral-domain ophthalmic imaging system that opens new doors to ophthalmologists to diagnose eye disease in infants, children, and disabled adults.
All eyes on Capitol Hill
A record number of ophthalmologists hit the hallways on Capitol Hill last month to urge their legislators to protect Americans' access to eye care and boost funding for eye research.
Use genetic testing with caution
Ophthalmologists should not order routine genetic tests for patients with common disorders like age-related macular degeneration until there are specific therapeutic interventions available to treat the disease based on the genetic information.
ARVO moves its annual meeting from Fort Lauderdale
Having the ARVO meeting in any of various locations enables the group to accommodate more program options and have a variety of hotel options nearby.
More supplies of counterfeit drug found
FDA investigators say counterfeit vials of Roche/Genentech's bevacizumab that have turned up in U.S. medical practices for the second time in 2 months have no active ingredient.
Thermal pulsation device clears gland blockages
The FDA clearance this past February for a second-generation version of a proprietary device allows physicians to treat both eyes simultaneously for meibomian gland dysfunction and evaporative dry eye in a relatively painless in-office procedure.
Dr. Lee becomes new University of Michigan chairman
Paul P. Lee, MD, JD, has come full circle. After earning his undergraduate and medical degrees from the University of Michigan in the 1980s, Dr. Lee has returned as chairman of the Department of Ophthalmology and Visual Sciences and holder of the F. Bruce Fralick scholarship.
Counterfeit bevacizumab found at oncology practices
Retina specialists who use compounded bevacizumab off-label to treat wet age-related macular degeneration are being warned that counterfeit vials of the cancer drug have turned up in oncology practices in the United States.
Valeant acquires Eyetech
Six years after OSI Pharmaceuticals Inc. bought Eyetech Pharmaceuticals Inc. for $650 million on the promise of its treatment for wet age-related macular degeneration, Valeant Pharmaceuticals International Inc. has announced it will acquire Eyetech for $22 million.
ISTA Pharmaceuticals plots next move
ISTA Pharmaceuticals says it is discussing a potential sale with a number of buyers, as Canada's biggest drug maker presses the board to accept its $360 million takeover bid.


View Results